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'mpyema thoracis (ET) represents a continuum of disease ranging from thin pleural fluid microscopically contaminated by organisms to gross purulence with dense deposition of fibiin and scar within the pleural space. The management ofET must be tailored to the character ofchanges within the pleural space and the patient condition. Most commonly, management of ET has consisted of administration of systemic antibiotics, with observation, thoracentesis, insertion of a chest tube, or decortication.
The use of intrapleural enzymatic agents for dissolution of ET was first described by Tillett and Sherry' in 1949. Streptokinase and streptodornase were used. More recently, other reports have described using purified streptokinase or urokinase to decrease the frequency of side effects. However, these reports have been sporadic and in small groups of patients. We describe a large consecutive group of patients treated with fibrinolytic therapy (FL) for ET.
MATERIALS AND METHODS
All patients referred for decortication for ET between December 1992 and November 1994 were considered for FL. ET was defined as the presence of documented infection by Gram signs of infection with complete drainage of fluid and no residual space radiographically (Fig 1) . Patients were not considered complete responders (CRs) if they received surgical intervention or were discharged from the hospital with empyema tubes in place. Partial responders (PR) had resolution of clinical symptoms and signs. These patients were discharged home from the hospital without surgical intervention, but with empyema tubes in place ( Fig  2) . All patients in this group had removal of empyema tubes within 30 days of completion of FL.
Nonresponders (NR) were patients who underwent decortication or empyema tube drainage for greater than 30 days after completion of FL (Fig 3) .
NRs were compared with responders (CRs and PRs) for age, duration ofempyema, initial temperature and WBC count, number of tubes and catheters, dosage of FL, number of treatments, length of hospitalization, fluid chemistries, and whether cultures grew organisms or were sterile. Platelet count, PT, and PTT before and after treatment were compared to determine whether coagulopathy had developed. Data There were no deaths. A significant complication occurred in only 1 patient (4%). He required 2 thoracotomies for oozing from rib fractures sustained 1 month prior to FL. This patient had coagulation studies prior to FL, results of which were normal. Minor complications included discomfort during instillation ofFL easily managed with narcotics. Fever was present in most patients but did not result in discontinuation of FL in any patient.
Follow-up was a minimum of 30 days from hospital discharge or removal of tubes, which ever was later. There was no recurrence of ET in any patient during this period. Patients were subsequently followed up by the medical and pulmonary services. However, no patient has been referred with recurrence subsequent to the 30-day surgical follow-up. DISCUSSION ET is thought to proceed through several welldescribed stages during maturation. In the exudative stage, a parapneumonic effusion develops and becomes secondarily infected. As infection progresses, the initially serous fluid becomes thick and purulent with organisms, fibrin, and WBCs. Thoracoscopy is useful for early loculated ET by allowing lysis of adhesion within the pleural space. However, general anesthesia is required, and the result achieved is the same as draining each loculation with a tube or catheter. In patients with trapped lung due to debris and early peel, neither complete drainage nor pneumolysis will be effective. Either chemical dissolution using FL or mechanical removal by decortication is required.
FL decreases empyema viscosity and dissolves loculations within the pleural space and therefore may resolve ET in patients in whom nonsurgical treatment has otherwise failed. Both streptokinase and urokinase convert plasminogen to plasmin. Plasmin dissolves fibrin and produces dissolution of loculations and early peels. Combined with chest tube drainage, this allows evacuation of fibropurulent empyemas that fail chest tube drainage alone. Both urokinase and streptokinase have been used in treatment of empyema. Urokinase is used most commonly because of the lower risk of anaphylaxis or other complication.'0
The efficacy of FL therapy for treatment of ET has been well documented in small series. In one recent series, Robinson et a12 described 13 patients with ET treated with streptokinase or urokinase intrapleural instillations. Although they reported 77% complete success, only 4 of 13 (31%) fulfilled our criteria for CR, ie, hospital discharge without empyema tubes. Six of 13 (46%) oftheir patients were discharged home from the hospital with empyema tubes in place. None of these tubes were removed within 30 days and would be considered nonresponsive by our criteria. Three of 13 (23%) were considered failures and required thoracotomy.
Moulton et al3 described 118 patients with complicated pleural disease. Fifty-seven patients had documented empyema based on culture, Gram's stain, or purulent drainage. Twenty-seven patients had sterile complicated parapneumonic effusions. FL was used in 98 (83%) of the entire group. The overall success rate with or without FL was 94%, mean duration of drainage was 6 days, and mean hospitalization was 20 days. Details for patients with empyema were not specified further.3 Other smaller series have reported success rates of up to 92%. 4- In this study, the CR rate was 62%, the PR was 8%, and the NR was 31%. Thus, more than two thirds of patients with traditional indication for decortication for ET were treated successfully with FL and without thoracotomy.
NRs had longer duration of symptoms and lower empyema glucose levels than responders, consistent with more advanced infections. The mean duration of symptoms in responders was 2 weeks (fibropurulent stage); these patients are expected to respond to FL. NRs had a mean duration of symptoms of 4.5 weeks (organized stage); they are less likely to respond to FL. These findings are similar to those reported by Moulton et al.3 Because the range of duration was wide in each group, duration of empyema should not be used as an exclusion criterion in patients being considered for FL.
NRs received significantly higher mean streptokinase dosages than responders. The failure to resolve empyemas in these patients suggests that doses of more than 250,000 IU are not necessary. The optimal dose of streptokinase per treatment is unknown.
Since responders had significantly more interventional catheters than NRs, improved drainage of loculations may have been partially responsible for the improved results compared with the NRs. However, all patients had CT scan verification of properly positioned drains and at least 24 h of 20 cm H20 suction prior to initiation of FL. This suggests that FL rather than catheters produced the response.
Although most responders had some residual pleural thickening radiographically, the natural history and significance of these findings are unknown. At least some of the patients showed continued radiographic improvement after removal of tubes in limited follow-up.
Our FL of choice during the study changed from streptokinase to urokinase. Both are relatively inexpensive ($87.88/250,000 IU vs $124.20/100,000 IU, respectively), but uroldinase, unlike streptokinase, is a native protein and therefore less likely to produce antibodies, allergic reaction, or anaphylaxis. The cost of urokinase treatment, based on the mean of 6.19 treatments per patient in this study, is estimated to be $768.80.
FL is associated with low morbidity and mortality and should be considered in the treatment of patients with ET. We suggest the following algorithm in treatment of patients with ET and without contraindications to FL: (1) drainage of all loculations using chest tubes or radiographically placed catheters using criteria above; (2) if this fails to completely expand the lung after 24 h of 20 cm H20 suction as documented with repeated CT scan, perform FL using 100,000 IU of intrapleural urokinase; FL is administered daily for 7 days, or less if radiographic resolution occurs, using tlle technique already described; drains are removed when CT scan confirms complete resolution of pleural fluid and cavities; (3) if no response results, proceed to empyema tube drainage or decortication; if partial improvement has occurred, perform FL for an additional 7 days, or less if CT documented resolution is achieved; and (4) if after 14 days of FL complete improvement is not reached, convert drains to empyema tubes or proceed to decortication.
